Last reviewed · How we verify
E7389 (Eribulin Mesylate)
Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth and induces apoptosis in cancer cells.
Eribulin is a microtubule dynamics inhibitor that suppresses microtubule growth and induces apoptosis in cancer cells. Used for Metastatic breast cancer, Liposarcoma, Other solid tumors (in clinical development).
At a glance
| Generic name | E7389 (Eribulin Mesylate) |
|---|---|
| Sponsor | Eisai Co., Ltd. |
| Drug class | Microtubule inhibitor |
| Target | Microtubules (β-tubulin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Eribulin mesylate is a non-taxane microtubule inhibitor derived from halichondrin B. It binds to microtubules and inhibits their growth phase while allowing shortening, leading to mitotic blockade and cancer cell death. It also exhibits anti-angiogenic properties and can reverse multidrug resistance.
Approved indications
- Metastatic breast cancer
- Liposarcoma
- Other solid tumors (in clinical development)
Common side effects
- Neutropenia
- Anemia
- Peripheral neuropathy
- Nausea
- Fatigue
- Alopecia
- Diarrhea
Key clinical trials
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (PHASE1, PHASE2)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (PHASE3)
- Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |